Biomedical Engineering Program, College of Engineering, University of Arkansas, 203 Engineering Hall, Fayetteville, AR 72701, USA.
Biosens Bioelectron. 2010 Dec 15;26(4):1650-5. doi: 10.1016/j.bios.2010.08.052. Epub 2010 Aug 23.
In vivo continuous glucose monitoring has posed a significant challenge to glucose sensor development due to the lack of reliable techniques that are non- or at least minimally-invasive. In this proof-of-concept study, we demonstrated the development of a new glucose sensor protein, AcGFP1-GBPcys-mCherry, and an optical sensor assembly, capable of generating quantifiable FRET (fluorescence resonance energy transfer) signals for glucose monitoring. Our experimental data showed that the engineered glucose sensor protein can generate measurable FRET signals in response to glucose concentrations varying from 25 to 800 μM. The sensor developed based on this protein had a shelf-life of up to 3 weeks. The sensor response was devoid of interference from compounds like galactose, fructose, lactose, mannose, and mannitol when tested at physiologically significant concentrations of these compounds. This new glucose sensor protein can potentially be used to develop implantable glucose sensors for continuous glucose monitoring.
体内连续血糖监测对葡萄糖传感器的发展提出了重大挑战，因为缺乏可靠的非侵入性或至少微创技术。在这项概念验证研究中，我们展示了一种新型葡萄糖传感器蛋白 AcGFP1-GBPcys-mCherry 的开发，以及一种光学传感器组件，能够产生可量化的 FRET（荧光共振能量转移）信号以进行葡萄糖监测。我们的实验数据表明，该工程化的葡萄糖传感器蛋白可以在 25 到 800 μM 的葡萄糖浓度范围内产生可测量的 FRET 信号。基于这种蛋白质开发的传感器在长达 3 周的保质期内保持稳定。当以这些化合物在生理相关浓度下进行测试时，该传感器的响应不受半乳糖、果糖、乳糖、甘露糖和甘露醇等化合物的干扰。这种新型葡萄糖传感器蛋白有可能用于开发可植入的葡萄糖传感器以进行连续血糖监测。
